RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to rescue patients from Hard-to-Treat lymphoma
Disease control TerminatedThis phase II trial tests a two-step approach for people with relapsed or refractory large B-cell lymphoma who are eligible for a stem cell transplant. First, patients receive tafasitamab (an antibody) plus lenalidomide, followed by tafasitamab combined with ICE chemotherapy. The…
Matched conditions: RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy duo takes on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…
Matched conditions: RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug cocktail aims to outsmart Hard-to-Treat lymphoma
Disease control OngoingThis phase 2 trial tests a combination of two drugs—TTI-622 and pembrolizumab (Keytruda)—in about 10 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. TTI-622 blocks a protein called CD47 that cancer cells use to hide from the immune syst…
Matched conditions: RECURRENT T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC